Loading company…
Novocure Ltd. develops Tumor Treating Fields (TTFields) cancer therapy, delivered via its Optune device for glioblastoma.
Founded in 2000 in the UK, Novocure Ltd. focuses on non-invasive cancer treatment, particularly Tumor Treating Fields, which use low-intensity electric fields to disrupt cancer cell division. Its Optune device lets glioblastoma patients receive therapy at home, and products are sold mainly in the United States and Germany. The company listed in an IPO in October 2015, raising USD 165.00 mn by selling 7.5 million shares at USD 22 each, and reported USD 351.30 mn in revenue in 2019.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in